South Korea Faces Vaccine Supply Crisis as GSK Exits Infant Market
South Korea’s infant vaccination program is facing a potential crisis as global pharmaceutical giant GSK announced it will discontinue the supply of its 5-valent combination vaccine, ‘Infanrix-IPV/Hib,’ starting June 30th. This follows the previous halt of its 4-valent vaccine, leaving the nation increasingly reliant on Sanofi for essential childhood immunizations. The situation highlights a critical vulnerability in South Korea’s healthcare security and underscores the urgent need for domestic vaccine production.
The Growing Dependence on Sanofi
Currently, only Sanofi and Boryeong Biopharma remain as suppliers of combination vaccines registered for the National Immunization Program (NIP). However, Boryeong Biopharma only offers a 4-valent option, meaning Sanofi’s 6-valent ‘Hexaxim’ and 5-valent ‘Pentaxim’ vaccines effectively dominate the market. This near-monopoly raises concerns about potential supply disruptions and price fluctuations.
Combination vaccines streamline the immunization process, reducing the number of injections infants require, and are generally preferred by parents. Before the registration of Hexaxim in January of last year, Pentaxim accounted for over 95% of infant vaccinations. Now, Hexaxim has become the dominant choice.
A History of Supply Issues
South Korea experienced a similar vaccine supply scare in late 2021. Administrative issues led to a temporary halt in the supply of GSK’s 5-valent and 4-valent vaccines, causing a surge in demand for Sanofi’s Pentaxim and resulting in shortages. Parents were forced to resort to administering separate Hib vaccines alongside the 4-valent option, a less convenient and potentially stressful solution. This event paved the way for Sanofi’s current market dominance.
The potential for a repeat of this scenario is now significantly higher with GSK’s complete withdrawal. Without alternative suppliers, even a minor disruption in Sanofi’s production or distribution could lead to widespread panic and jeopardize the nation’s immunization schedule.
The Promise of Domestic Vaccine Development
LG Chem is currently developing both advanced and low-cost 6-valent combination vaccines. Their ‘YUPENTA’ vaccine utilizes a whole-cell pertussis (wP) component, making it more affordable for low-income countries. They are also developing ‘APV006,’ a 6-valent vaccine with an acellular pertussis (aP) component, designed for developed markets like South Korea.
However, LG Chem’s timeline for commercialization is ambitious, with both vaccines projected to be available by 2030. The development of aP vaccines is more complex and costly, requiring rigorous clinical trials and regulatory approvals.
Pro Tip: Investing in domestic vaccine production isn’t just about cost savings; it’s about national security. A reliable domestic supply chain ensures access to critical vaccines during global health crises.
The Role of WHO PQ Certification
LG Chem’s YUPENTA vaccine has already received World Health Organization (WHO) Prequalification (PQ) certification, allowing it to be supplied to low-income countries through UNICEF. This demonstrates the company’s manufacturing capabilities and commitment to global health. However, obtaining approval for use within South Korea requires additional clinical trials and regulatory hurdles.
Challenges and the Need for Government Support
Conducting clinical trials for NIP-registered vaccines in South Korea is challenging due to the availability of free vaccinations. Recruiting participants willing to undergo trials when a free alternative exists is difficult. Industry experts emphasize the need for government support to accelerate the development and approval process for domestic vaccines.
Did you know? The acellular pertussis (aP) component in some vaccines reduces the risk of fever and swelling after vaccination, but it also increases manufacturing complexity and cost.
FAQ: South Korea’s Vaccine Supply
- What vaccines are affected by GSK’s decision? GSK is discontinuing its 5-valent (Infanrix-IPV/Hib) vaccine.
- Who will supply vaccines now? Primarily Sanofi and Boryeong Biopharma.
- When will LG Chem’s vaccines be available? Both vaccines are projected for commercialization by 2030.
- Why is domestic vaccine production important? It enhances national healthcare security and reduces reliance on foreign suppliers.
The situation demands a proactive approach from the South Korean government and pharmaceutical industry. Accelerating domestic vaccine development, streamlining regulatory processes, and fostering collaboration between public and private sectors are crucial steps to ensure a stable and secure vaccine supply for future generations.
[Hot Click]
· Seoul Redevelopment Hotspots in 2024
· CES 2024: A Ride on the Vegas Loop
· The Fall of Kim Byung-ju: A Homeplus Saga
· South Korea’s Steel Industry Faces Triple Threat
· Clean Nara Succession: The Path Ahead
Explore more articles on healthcare and pharmaceutical trends here. Subscribe to our newsletter for the latest updates!
Related reading